By What Percentage Did J&J’s Revenue & EBITDA Grow In The Last 5 Years?
- 14% Revenue Growth Driven By Immunology & Cancer Drugs
- 20% EBITDA Growth Driven By Revenue Increase And Margin Expansion
Relevant Articles
- Which Is A Better Pick: JNJ Stock Or ABBV Stock?
- Should You Pick JNJ Stock After An Upbeat Q3?
- What To Expect From Johnson & Johnson’s Q3?
- Is Disney A Better Pick From The Dow Jones Index Over Johnson & Johnson Stock ?
- Johnson & Johnson Poised To Do Well, But Are These Steady Eddie Stocks Better Bets?
- JNJ Stock A Winner Right Now?
Have more questions about Johnson & Johnson? See the links below.
- How J&J’s Increased Focus On Pharmaceuticals Has Helped Its Financials?
- Drugs, Devices, Consumer: What’s Johnson & Johnson’s Revenue and Earnings breakdown?
- What’s J&J’s Fundamental Value Based On Expected 2015 Results?
- How Increased Focus On Pharmaceuticals In The Last 5 Years Has Helped J&J?
- By How Much Can J&J’s Revenue And EBITDA Grow Over The Next 3 Years?
- What Percentage Of Its Revenue Could J&J Lose Solely Due To Patent Losses Over The Next 5 Years?
Note: The figures mentioned are approximate values to help our readers remember and grasp the concept more intuitively. For accurate figures, please refer to our complete analysis for Johnson & Johnson
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)